Prospects for stem cell transplantation in multiple sclerosis

Journal of Clinical Neuroscience

Volumn 9, Issue 4, 2002, Pages 361-367

  Kilpatrick, Trevor J ^a   Butzkueven, Helmut ^a   Grigg, Andrew ^a  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

Author keywords

Cladribine; Cyclophosphamide; Multiple sclerosis; Stem cell transplantation

Indexed keywords

BETA INTERFERON; CARMUSTINE; CD3 ANTIGEN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GLATIRAMER; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; METHYLPREDNISOLONE; MITOXANTRONE; PREDNISOLONE; THYMOCYTE ANTIBODY;

ALLERGIC ENCEPHALOMYELITIS; AUTOIMMUNE DISEASE; GRAFT VERSUS HOST REACTION; HLA MATCHING; IMMUNE MEDIATED INJURY; IMMUNOSUPPRESSIVE TREATMENT; LEUKAPHERESIS; MULTIPLE SCLEROSIS; OUTCOMES RESEARCH; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION;

EID: 0036655742     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1054/jocn.2001.0990     Document Type: Review

References (30)

1. Compston A, Ebers G, Lassmann H et al. McAlpine's Multiple Sclerosis. 3rd ed. Edinburgh: Churchill Livingstone, 1998.
2. IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993; 43: 655-661.
3. Jacobs LD, Cookfair DL, Rudick RA et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39: 285-294.
4. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
5. Johnson KP, Brooks BR, Cohen JA et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis. Neurology 1995; 45: 1268-1276.
6. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998; 352: 1491-1497.
7. Burt RK, Burns W, Hess A. Bone marrow transplantation for multiple sclerosis. Bone Marrow Transplant 1995; 16: 1-6.
8. Cooley HM, Snowden JA, Grigg AP et al. Outcome of rheumatoid arthritis and psoriasis following autologous stem cell transplantation for hematologic malignancy. Arthritis Rheum 1997; 40: 1712-1715.
9. Snowden JA, Kearney P, Kearney A et al. Long-term outcome of autoimmune disease following allogeneic bone marrow transplantation. Arthritis Rheum 1998; 41: 453-459.
10. Burt RK, Burns WH, Miller SD. Bone marrow transplantation for multiple sclerosis: returning to Pandora's box. Immunol Today 1997; 18: 559-561.
11. Burt RK, Padilla J, Dal Canto MC et al. Viral hyperinfection of the central nervous system and high mortality after hematopoietic stem cell transplantation for treatment of Theiler's murine encephalomyelitis virus-induced demyelinating disease. Blood 1999; 94: 2915-2922.
12. Arbona C, Prosper F, Benet I et al. Comparison between once a day vs twice a day G-CSF for mobilization of peripheral blood progenitor cells (PBPC) in normal donors for allogeneic PBPC transplantation. Bone Marrow Transplant 1998; 22: 39-45.
13. Openshaw H, Stuve O, Antel JP et al. Multiple sclerosis flares associated with recombinant granulocyte colony-stimulating factor. Neurology 2000; 54: 2147-2150.
14. Champlin R, Ho W, Gale RP. Antithymocyte globulin treatment in patients with aplastic anemia: a prospective randomized trial. N Engl J Med 1983; 308: 113-118.
15. Openshaw H, Slatkin NE, Stein AS et al. Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Cancer 1996; 78: 1899-1905.
16. Openshaw H, Lund BT, Kashyap A et al. Peripheral blood stem cell transplantation in multiple sclerosis with busulfan and cyclophosphamide conditioning: report of toxicity and immunological monitoring. Biol Blood Marrow Transplant 2000; 6: 563-575.
17. Burt RK, Traynor AE, Cohen B et al. T cell-depleted autologous hematopoietic stem cell transplantation for multiple sclerosis: report on the first three patients. Bone Marrow Transplant 1998; 21: 537-541.
18. Kremenchutzky M, Cottrell D, Rice G et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. Brain 1999; 122: 1941-1950.
19. Nash R et al. Basic and clinical issues in multiple sclerosis research treatment of severe multiple sclerosis (MS) with high-dose immunosuppressive therapy and autologous stem cell transplantation. ACTRIMS 2000; 8.
20. Burt RK, Traynor AE, Pope R et al. Treatment of autoimmune disease by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood 1998; 92: 3505-3514.
21. Fassas A, Anagnostopoulos A, Kazis A et al. Autologous stem cell transplantation in progressive multiple sclerosis - an interim analysis of efficacy. J Clin Immunol 2000; 20: 24-30.
22. Tyndall A, Fassas A, Passweg J et al. Autologous haematopoietic stem cell transplants for autoimmune disease - feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League Against Rheumatism and the International Stem Cell Project for Autoimmune Disease. Bone Marrow Transplant 1999; 24: 729-734.
23. Kozak T, Havrdova E, Pit'ha J et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 2000; 25: 525-531.
24. Kilpatrick TJ, Butzkueven H. Immunosuppressive therapy is valuable in aggressive multiple sclerosis. J Clin Neurosci 2000; 7: 561-563; discussion 564-565.
25. Sipe JC, Romine JS, Koziol JA et al. Cladribine in treatment of chronic progressive multiple sclerosis. Lancet 1994; 344: 9-13.
26. Rice GP, Filippi M, Comi G. Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 2000; 54: 1145-1155.
27. Hartung HP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, randomised, observer-blind Phase III Trial: clinical results and three-year follow-up. Neurology 1999; 52: A290.
28. Ascherio A, Zhang SM, Hernan MA et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001; 344: 327-332.
29. Burt RK, Padilla J, Begolka WS et al. Effect of disease stage on clinical outcome after syngeneic bone marrow transplantation for relapsing experimental autoimmune encephalomyelitis. Blood 1998; 91: 2609-2616.
30. Fassas A, Anagnostopoulos A, Kazis A et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997; 20: 631-638.